Pharmaceutical Executive-03-01-2021

What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.

Meaningful biopharma sustainability metrics are a crucial challenge.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Michael Bailey, CEO of AVEO Oncology, discusses how his ultimate leadership path in biotech—the setbacks and “long slog of ups and downs”—continues to shape a patient-focused mission on bridging product development and commercialization to advance drugs for unmet need in cancer.

Amid vaccine heroics, its complex story may finally be resonating.

Treat patents as strategic business assets and build an IP portfolio.

Disputes over mRNA-related patents are poised to persist.

Industry makes large investments toward public health issues exposed by pandemic.

Efforts made to ensure drug quality, reviews amid pandemic.

Fighting the pandemic with joint projects and IP sharing.

Click the title above for a link to open the Pharmaceutical Executive March 2021 issue in an interactive PDF format.

Looking back at 1986-1989.

Open communication gives people the opportunity to explore.

Recruitment of data scientists is much more than a numbers game.

Latest proposal explores boosting the powers of the EMA.

Tracing biopharma’s innovation evolution—and, framed by COVID-19 and the med-tech boon, a look at four notable efforts focused on that one elusive constant: translational value.

How the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.